REVOLUTION MED. DL-0001
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more
REVOLUTION MED. DL-0001 (42Z) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, REVOLUTION MED. DL-0001 (42Z) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
REVOLUTION MED. DL-0001 - Net Assets Trend (None–None)
This chart illustrates how REVOLUTION MED. DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for REVOLUTION MED. DL-0001 (None–None)
The table below shows the annual net assets of REVOLUTION MED. DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to REVOLUTION MED. DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
REVOLUTION MED. DL-0001 Competitors by Market Cap
The table below lists competitors of REVOLUTION MED. DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jacobs Solutions Inc.
NYSE:J
|
$15.27 Billion |
|
Julius Bär Gruppe AG
XETRA:JGE
|
$15.28 Billion |
|
Asahi Group Holdings Ltd
PINK:ASBRF
|
$15.32 Billion |
|
Hangzhou Hikvision Digital Technology Co Ltd
SHE:002415
|
$15.32 Billion |
|
MKS Instruments Inc
NASDAQ:MKSI
|
$15.27 Billion |
|
Cathay Financial Holding Co Ltd Pref A
TW:2882A
|
$15.23 Billion |
|
Itaúsa - Investimentos Itaú SA
SA:ITSA3
|
$15.22 Billion |
|
Sonova Holding AG
PINK:SONVF
|
$15.21 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in REVOLUTION MED. DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares REVOLUTION MED. DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently REVOLUTION MED. DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares REVOLUTION MED. DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| REVOLUTION MED. DL-0001 (42Z) | €- | N/A | N/A | $15.27 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |